Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis
Details
Publication Year 2020-10-20, Volume 11, Issue #10, Page 877
Journal Title
Cell Death & Disease
Publication Type
Journal Article
Abstract
TP53 is a critical tumor suppressor that is mutated in approximately 50% of human cancers. Unveiling the downstream target genes of TP53 that fulfill its tumor suppressor function is an area of intense investigation. Zmat3 (also known as Wig-1 or PAG608) is one such downstream target of p53, whose loss in hemopoietic stem cells lacking the apoptosis and cell cycle regulators, Puma and p21, respectively, promotes the development of leukemia. The function of Zmat3 in tumorigenesis however remains unclear. Here, to investigate which oncogenic drivers co-operate with Zmat3 loss to promote neoplastic transformation, we utilized Zmat3 knockout mice in models of c-MYC-driven lymphomagenesis and Kras(G12D)-driven lung adenocarcinoma development. Interestingly, unlike loss of p53, Zmat3 germline loss had little impact on the rate of tumor development or severity of malignant disease upon either the c-MYC or Kras(G12D) oncogenic activation. Furthermore, loss of Zmat3 failed to rescue Kras(G12D) primary lung tumor cells from oncogene-induced senescence. Taken together, we conclude that in the context of c-MYC-driven lymphomagenesis or mutant Kras(G12D)-driven lung adenocarcinoma development, additional co-occurring mutations are required to resolve Zmat3 tumor suppressive activity.
Publisher
NPG
WEHI Research Division(s)
Cancer Biology And Stem Cells; Advanced Technology And Biology; Blood Cells And Blood Cancer
PubMed ID
33082333
Open Access at Publisher's Site
https://doi.org/10.1038/s41419-020-03066-9
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2021-02-01 12:05:16
Last Modified: 2021-03-02 10:06:16
An error has occurred. This application may no longer respond until reloaded. Reload 🗙